Vorbipiprant
As of the edition of 20 October 2026, Vorbipiprant is a small molecule: in active development; acts on PTGER4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Digestive system; Bones, joints and muscles; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGER4 | Prostaglandin E2 receptor EP4 subtype | P35408 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 1 | 2 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Rottapharm Biotech | Lead sponsor of trials | 2017 to now |